Replimune Group Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
REPL Nasdaq 8731 https://www.replimune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Replimune Group Inc

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate - Oct 2nd, 2024 12:02 pm
Replimune to Present at Two Upcoming Investor Conferences - Oct 1st, 2024 12:00 pm
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - Sep 15th, 2024 1:45 pm
Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 - Sep 9th, 2024 12:00 pm
Stockholders Vote to Elect Madhavan Balachandran to Board of Directors - Sep 5th, 2024 12:00 pm
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 - Aug 22nd, 2024 12:00 pm
Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy - Aug 14th, 2024 8:33 pm
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma - Aug 13th, 2024 12:00 pm
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update - Aug 8th, 2024 12:00 pm
Replimune Announces $100 Million Private Placement Financing - Jun 13th, 2024 12:30 pm
Replimune (REPL) Gains on Positive Data From Melanoma Study - Jun 7th, 2024 1:03 pm
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Jun 7th, 2024 12:00 pm
Sector Update: Health Care Stocks Higher in Late Afternoon Trading - Jun 6th, 2024 8:00 pm
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Jun 6th, 2024 4:16 pm
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma - Jun 6th, 2024 11:00 am
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 3rd, 2024 12:00 pm
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024 9:00 pm
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update - May 16th, 2024 12:00 pm
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting - Apr 7th, 2024 9:00 pm
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 4th, 2024 12:00 pm